This report was first published by Endpoints News. To see the original version, click here
During the hoopla of a $10 billion bidding war for Metsera earlier this month, another obesity biotech startup was also acquired, but much more quietly and to little fanfare.
Tucked into AstraZeneca’s third-quarter earnings update, the UK pharma giant disclosed that it exercised its option to buy out Swiss startup SixPeaks Bio. The deal involved $170 million at closing with up to $130 million more on the line.
您已閱讀10%（502字），剩余90%（4755字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。